Tu1440: LONG-TERM CUMULATIVE SAFETY OF USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS

Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Silvio Danese(IRCCS Ospedale San Raffaele), Christopher Gasink(Janssen (United States)), Stephen B. Hanauer(Northwestern University), Colleen Marano(Johnson & Johnson (United States)), Miao Ye, Tony Ma, Emese Mihály(Semmelweis University), Raquel Vicente(Hospital Universitario Miguel Servet), E. Ott, Vipul Jairath(Western University)
Gastroenterology
May 1, 2022
10.1016/s0016-5085(22)62278-9
Cited by 0

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k